Clinical Trial Update: Metronomic Capecitabine Plus Aromatase Inhibitor for First Line Treatment in HR(+), Her2(-) Metastatic Breast Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating metronomic capecitabine plus an aromatase inhibitor as first-line therapy for HR-positive, HER2-negative metastatic breast cancer has c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Hormone Receptor-positive Breast Cancer

Drugs mentioned

• Aromatase inhibitor (Aromatase inhibitor)
• Xeloda (capecitabine)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Breast Cancer | Phase 3 | Status: COMPLETED